Search
KAND567
go.drugbank.com/drugs/DB16511InvestigationalBecause COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908]. … KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908].
Categories: Experimental Unapproved Treatments for COVID-19Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
ATX-F8-117
go.drugbank.com/drugs/DB17712ExperimentalATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedNeurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fer...
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedThe marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer. … In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health.
Categories: Adrenergic alpha-2 Receptor AgonistsSovateltide
go.drugbank.com/drugs/DB06138InvestigationalSPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. … It is being developed as an adjunct to chemotherapy.
Rimiducid
go.drugbank.com/drugs/DB04974Investigational[A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation. … It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.
Talizumab
go.drugbank.com/drugs/DB05797ExperimentalTNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.